Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EP53 lipid nanoparticles
- Development stage
- Unknown
- Lead developer
- PEEL Therapeutics
- Modality
- Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous (anticipated; Typical For LNP-based Therapies)
01
Overview
EP53 lipid nanoparticles are a gene therapy in preclinical development by Peel Therapeutics. This therapy is designed to deliver the elephant version of the p53 tumor suppressor gene (EP53) using a lipid nanoparticle delivery system. The rationale is based on elephants’ natural cancer resistance, attributed to their multiple copies of the TP53 gene—a key regulator of cell cycle and apoptosis that is often inactivated in human cancers. By delivering functional elephant p53 via advanced nanotechnology, this approach aims to restore or enhance tumor suppression in solid tumors. The technology leverages expertise in both evolutionary biology and nanomedicine for targeted delivery and reduced toxicity[1][2][3][6].
- Other names
- Elephant P53 Lipid NanoparticlesEP53-LNPsEP-53-LNPsEP 53-LNPs
02
Targets
TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on EP53 lipid nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EP53 lipid nanoparticles.